Starpharma to begin Phase I dendrimer-docetaxel study

Australia-based Starpharma has received necessary approvals to start a Phase I human clinical trial of its dendrimer-docetaxel (Taxotere) chemotherapeutic product, referred to as DEP-Docetaxel, for the treatment of solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news